• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Staying on the Sidelines With Best Buy for Now

I don't love it, but I don't hate it.
By TIMOTHY COLLINS
Sep 25, 2019 | 12:03 PM EDT
Stocks quotes in this article: BBY, WMT, TGT, AMZN

Very few people can project where they will be in five years, so why do we think businesses can do it as well. There are so many variables that arise, wane, and simply change over half-a-decade. Don't get me wrong, it's cute when businesses do it, but it's more about the PR and being able to say "we have a plan, we know where we are headed" than actual expectations of reality.

Best Buy (BBY) management is targeting $50 billion in enterprise revenue in 2025 compared to their current guidance of $43.5 billion in fiscal year 2020. That's not exactly lighting the world on fire in terms of revenue growth. Through $1 billion in cost reductions and efficiencies, the company believes it can increase non-GAAP operating income to 5% compared to the current 4.6% rate which would be a small boost to the bottom line.

The biggest excitement stems from the potential of Best Buy Health. The company seeks to take advantage of an aging population by jumping into the healthcare space. The thing is the company has already entered the space with its $800 million purchase of Great Call, a company designed to provide health and emergency services to seniors via emergency-response systems. Best Buy wants to add health monitoring systems for seniors as well as the sale of fitness machines and health equipment to the mix.

You're going to hear HUGE healthcare numbers in terms of potential revenue, but remember this is only a small slice of the pie. The medical device offerings from Best Buy are likely to skew to the basic side of the medical device market. I would imagine competition from Amazon (AMZN) , Walmart (WMT) , and Target (TGT) would quickly come online should the equipment/technology side gain traction. Could we see Peleton beside NordicTrack and ProForm in the stores? Sure. Will it help the top line? I believe it will. However, until we see proof this will positively impact the bottom line, I'm not a buyer based on the potential here. It's going to be highly competitive and margins will thin out quickly.

In terms of trading the stock, a pullback to weekly support has been the best entry. That would put traders in the position to look long around $63 with a stop in the $59 to $60 range. A weekly close over $68.50 would also be intriguing on the long side as it would place shares above short-term resistance and into the middle of the 2019 range with an upside potential of $75 to $77. The stock has struggled under the 20-week simple moving average (SMA), so there is no reason to be long under it unless we test and hold the previously mentioned support. Above the 20-week SMA provides for a nice hedge/stop point using that moving average.

This one falls into the I don't love it, but I don't hate it category, but that's a view that keeps me on the sidelines for now.

(Amazon is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells AMZN? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Earnings | Investing | Options | Stocks | Technical Analysis | Trading | Healthcare | Retail | Stock of the Day

More from Investing

UnitedHealth Has Recovered Above a Key Indicator

Bruce Kamich
Jul 7, 2022 10:03 AM EDT

Here's our latest technical strategy on UNH shares.

How Does Levi's Size Up Ahead of Earnings?

Bruce Kamich
Jul 7, 2022 9:34 AM EDT

Let's check the charts and indicators.

A Few Thoughts on What to Do With ARKK and QQQ

Bob Byrne
Jul 7, 2022 8:30 AM EDT

The latter shows a bit of relative strength, while the former looks to break above resistance.

Cytokinetics Is Showing Its Muscles on the Charts

Bruce Kamich
Jul 7, 2022 8:18 AM EDT

In light of the stock market's weakness, CYTK has shown impressive strength.

The Market Awaits the Next Macroeconomic Catalyst

James "Rev Shark" DePorre
Jul 7, 2022 7:52 AM EDT

Unemployment reports are on deck, and then the next Fed rate hike.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:41 AM EDT STEPHEN GUILFOYLE

    Reweighting Portfolio Positions Through 5 Trades

    Check out what we're doing in the TheStreet's Stoc...
  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login